9.04
-0.10 (-1.09%)
Market Trend
| Short Term | Medium Term | ||
| Industry | Biotechnology (US) | Mixed | Mixed |
| Biotechnology (Global) | Mixed | Mixed | |
| Stock | Jade Biosciences, Inc. | Bullish | - |
AIStockmoo Score
| Analyst Consensus | 3.0 |
| Insider Activity | 3.0 |
| Price Volatility | 0.5 |
| Technical Moving Averages | 1.5 |
| Technical Oscillators | 2.0 |
| Average | 2.00 |
|
Jade Biosciences Inc is focused on developing therapies to address critical unmet needs in autoimmune diseases. Its asset, JADE-001, will target the anti-A PRoliferation-Inducing Ligand (APRIL) pathway for immunoglobulin A (IgA) nephropathy, with Investigational New Drug Application-enabling studies underway and initiation of a first-in-human trial. Jade’s pipeline also includes two undisclosed optimized antibody discovery programs, JADE-002 and JADE-003, currently in preclinical development. Jade was launched based on assets licensed from Paragon Therapeutics, an antibody discovery engine founded by Fairmount. |
|
| Sector | Healthcare |
| Industry | Biotechnology |
| % Held by Insiders | 0.04% |
| % Held by Institutions | 33.40% |
Ownership
| Name | Date | Shares Held |
|---|---|---|
| Versant Venture Management, Llc | 30 Jun 2025 | 1,525,820 |
| 52 Weeks Range | ||
| Price Target Range | ||
| High | 28.00 (BTIG, 209.74%) | Buy |
| Median | 23.00 (154.43%) | |
| Low | 18.00 (Wedbush, 99.12%) | Buy |
| Average | 23.00 (154.43%) | |
| Total | 2 Buy | |
| Avg. Price @ Call | 8.09 | |
| Firm | Date | Target Price | Call | Price @ Call |
|---|---|---|---|---|
| BTIG | 09 Oct 2025 | 28.00 (209.73%) | Buy | 9.40 |
| Wedbush | 14 Aug 2025 | 18.00 (99.12%) | Buy | 6.77 |
| Name | Avg. Buy ($) | Avg. Sell ($) | Net Quantity | Net Value ($) |
|---|---|---|---|---|
| FAIRMOUNT FUNDS MANAGEMENT LLC | 9.14 | - | 1,333,126 | 12,184,772 |
| Aggregate Net Quantity | 1,333,126 | |||
| Aggregate Net Value ($) | 12,184,772 | |||
| Aggregate Avg. Buy ($) | 9.14 | |||
| Aggregate Avg. Sell ($) | - | |||
| Name | Holder | Date | Type | Quantity | Price | Value ($) |
|---|---|---|---|---|---|---|
| FAIRMOUNT FUNDS MANAGEMENT LLC | Director | 06 Oct 2025 | Acquired (+) | 1,333,126 | 9.14 | 12,184,772 |
The support, resistance and trendline levels presented has been generated by an artificial intelligence (AI) model and should be interpreted with caution.
Portfolio
| Realized Profit | - |
| Unrealized Profit | - |
| Dividend Received 2025 | - |
| Total Profit | - |
| Avg. Return | - |
| Quantity (Buy) | - |
| Avg. Price (Buy) | - |
| Quantity (Sold) | - |
| Avg. Price (Sold) | - |